Core Insights - Eli Lilly reported Q4 earnings that exceeded analyst expectations, with a profit of $7.54 per share on sales of $19.3 billion, compared to forecasts of $6.93 per share on $17.9 billion in sales [1] - Despite strong earnings, Eli Lilly's stock fell 6% due to competitive pressures from Hims & Hers Health, which announced a new "needle-free" GLP-1 weight loss pill [1][3] Group 1: Eli Lilly's Performance - Eli Lilly's Q4 earnings beat expectations, forecasting full-year 2026 earnings between $33.50 and $35 per share [1] - The company achieved significant sales driven by injectable GLP-1 weight loss drugs Mounjaro and Zepbound in 2025 [2] Group 2: Competitive Landscape - Hims & Hers Health introduced a compounded semaglutide pill priced at $49 for the first month, which is significantly lower than Eli Lilly's Zepbound price of $299 for the lowest-dose formulation [3][4] - Hims & Hers plans to increase the price of its GLP-1 pill to $99 per month after the introductory period, but it remains competitive compared to Novo Nordisk's pricing [4][5] - Novo Nordisk offers its injectable Wegovy at $199 and its pill form at $149, indicating a competitive pricing environment for GLP-1 drugs [4]

Group 1 - Apyx Medical is positioning itself as a leader in the surgical aesthetics market, emphasizing that surgical aesthetics provide durable and transformational results for patients [4] - The company is launching a new product, AYON, which will be a focal point of the event [3] - The market dynamics have been notably influenced by the introduction of GLP-1 drugs for weight loss, which has changed the landscape of surgical aesthetics [4] Group 2 - The event features Dr. Vanek as a key opinion leader (KOL), who will share his experiences with the AYON product [2][3] - The agenda includes an introduction by the CEO, a discussion on the commercial launch of AYON, and a Q&A session at the end [3]